Valeris Debuts Comprehensive Vision for Biotech and Life Sciences Businesses
**Valeris: A Game-Changer in Life Sciences Commercialization**
In a significant move for the biopharmaceutical industry, the merger of Mercalis and PharmaCord has resulted in the formation of Valeris, a leading provider of patient support services [1][3][4]. This strategic combination, announced in March 2025, aims to redefine how life sciences companies bring innovative therapies to life.
**Who is Valeris?**
Valeris is a newly rebranded and consolidated entity that leverages the strengths of both Mercalis and PharmaCord. It serves as a comprehensive platform designed to support life sciences firms in navigating today's outcomes-driven healthcare landscape by providing integrated solutions that link pharmaceutical companies, providers, and patients more effectively [1][3][4].
**Valeris' Solutions Across the Healthcare Value Chain**
Valeris offers solutions that span multiple critical aspects of the healthcare value chain. These include:
1. **Therapy Delivery Optimization**: Valeris enhances how therapies are brought to market and used by patients through improved logistics, patient support, and distribution models [4].
2. **Integrated Partnerships**: Valeris facilitates strategic, measurable collaborations between pharmaceutical companies and integrated delivery networks (IDNs), helping shift from traditional sales to value-based, outcomes-focused partnerships [1].
3. **Pharmacy and Distribution Services**: Drawing on PharmaCord’s expertise, Valeris delivers specialty pharmacy and infusion services, supporting complex therapy administration and patient management, especially in specialty and rare disease segments [2].
4. **Digital and Data-Driven Tools**: Emphasizing digital transformation, Valeris optimizes clinical trials, patient outcomes, and lifecycle management in drug development and commercialization [3].
Valeris is committed to enhancing the patient experience by streamlining access, reducing barriers, and supporting adherence. The company's comprehensive solutions are purpose-built to address the challenges of today's complex healthcare landscape.
**Valeris' Backing and Leadership**
Valeris is backed by global investment firms Permira and Odyssey Investment Partners. Rob Truckenmiller serves as the Chief Executive Officer, while Scott Dulitz is the President of Valeris. For more information about Valeris, visit www.valeris.com, or contact Landy Townsend, VP, Marketing & Communications, at [email protected] [5].
[1] https://www.valeris.com/news/valeris-announces-merger-of-mercalis-and-pharmacord [2] https://www.valeris.com/services/specialty-pharmacy-services [3] https://www.valeris.com/services/data-analytics-and-insights [4] https://www.valeris.com/services/patient-support-services [5] Media contact: Landy Townsend, VP, Marketing & Communications, Valeris ([email protected])
Valeris, the newly-formed life sciences company, is backed by global investment firms Permira and Odyssey Investment Partners. They aim to redefine how life sciences companies bring innovative therapies to life by providing cloud-based financial infrastructure and data-driven news for better business decisions.
As a comprehensive platform, Valeris serves life sciences firms by offering integrated solutions, improving therapy delivery, establishing integrated partnerships, providing pharmacy and distribution services, and utilizing digital and data-driven tools for optimized clinical trials, patient outcomes, and lifecycle management.
